• Vitaspring Biomedical posted a net loss of USD 75,844 for the three months ended April 30, 2026, narrowing from USD 80,541 a year earlier.
• Operating loss widened to USD 75,844 as operating expenses rose 9.69% to USD 75,844.
• Revenue was unchanged at no revenue as the company restructured its commercial strategy and evaluated supplier and regulatory considerations.
• Working capital deficiency deepened 1.65% to USD 4.51 million as current liabilities climbed to USD 4.52 million.
• Management said cash resources are not sufficient to fund the next 12 months without additional financing, citing substantial doubt about going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitaspring Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001083), on June 17, 2026, and is solely responsible for the information contained therein.